Panama7/iStock Editorial via Getty Images
- Sanofi (NASDAQ:SNY) said the FDA has accepted for priority review the supplemental Biologics License Application for the investigational use of Sarclisa in combination with bortezomib, lenalidomide and dexamethasone for the treatment of patients with transplant-ineligible newly diagnosed multiple myeloma.
- Multiple myeloma is a type of blood cancer that develops in the plasma cells.
- The target action date for the FDA decision is September 27, 2024, the firm said.
- The company added, a regulatory submission was also under review in the European Union.
